Zimmer Biomet Holdings Stock Total Debt
| ZBH Stock | USD 104.92 2.43 2.26% |
Zimmer Biomet Holdings fundamentals help investors to digest information that contributes to Zimmer Biomet's financial success or failures. It also enables traders to predict the movement of Zimmer Stock. The fundamental analysis module provides a way to measure Zimmer Biomet's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zimmer Biomet stock.
Zimmer |
Zimmer Biomet Holdings Company Total Debt Analysis
Zimmer Biomet's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Zimmer Biomet Total Debt | 6 B |
Most of Zimmer Biomet's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zimmer Biomet Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Zimmer Biomet Holdings has a Total Debt of 6 B. This is 117.92% higher than that of the Health Care Equipment & Supplies sector and 243.17% higher than that of the Health Care industry. The total debt for all United States stocks is 12.75% lower than that of the firm.
Zimmer Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zimmer Biomet's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zimmer Biomet could also be used in its relative valuation, which is a method of valuing Zimmer Biomet by comparing valuation metrics of similar companies.Zimmer Biomet is currently under evaluation in total debt category among its peers.
Zimmer Fundamentals
| Return On Equity | 0.0725 | ||||
| Return On Asset | 0.0459 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 27.05 B | ||||
| Shares Outstanding | 199.07 M | ||||
| Shares Owned By Insiders | 0.29 % | ||||
| Shares Owned By Institutions | 93.28 % | ||||
| Number Of Shares Shorted | 7.42 M | ||||
| Price To Earning | 77.41 X | ||||
| Price To Book | 1.71 X | ||||
| Price To Sales | 2.78 X | ||||
| Revenue | 2.02 B | ||||
| Gross Profit | 5.51 B | ||||
| EBITDA | 2.57 B | ||||
| Net Income | 1.02 B | ||||
| Cash And Equivalents | 375.7 M | ||||
| Cash Per Share | 2.71 X | ||||
| Total Debt | 6 B | ||||
| Debt To Equity | 0.48 % | ||||
| Current Ratio | 1.98 X | ||||
| Book Value Per Share | 62.66 X | ||||
| Cash Flow From Operations | 1.58 B | ||||
| Short Ratio | 4.39 X | ||||
| Earnings Per Share | 4.43 X | ||||
| Price To Earnings To Growth | 1.47 X | ||||
| Target Price | 121.85 | ||||
| Number Of Employees | 33 | ||||
| Beta | 1.02 | ||||
| Market Capitalization | 21.37 B | ||||
| Total Asset | 21.5 B | ||||
| Retained Earnings | 10.38 B | ||||
| Working Capital | 1.75 B | ||||
| Current Asset | 5.85 B | ||||
| Current Liabilities | 1.62 B | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 0.75 % | ||||
| Net Asset | 21.5 B | ||||
| Last Dividend Paid | 0.96 |
About Zimmer Biomet Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zimmer Biomet Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zimmer Biomet using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zimmer Biomet Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:Check out Zimmer Biomet Piotroski F Score and Zimmer Biomet Altman Z Score analysis. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.